Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals has reported encouraging early Phase 1b combination data for ORIC-944 in treating metastatic castration-resistant prostate cancer (mCRPC). The trial showed deep PSA decreases, with 3 of 6 patients achieving confirmed PSA50 responses and 2 achieving PSA90 responses. The treatment demonstrated favorable safety with primarily Grade 1 and 2 adverse events.
The company entered a clinical collaboration with Johnson & Johnson to evaluate ORIC-114 combined with amivantamab for first-line NSCLC treatment. ORIC expects seven data readouts across its clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026.
Following a $125 million private placement financing, ORIC's cash position stood at $282.4 million as of September 30, 2024, expected to fund operations into late 2026.
ORIC Pharmaceuticals announced a clinical supply agreement with Janssen Research & Development to evaluate ORIC-114 in combination with amivantamab for the first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This Phase 1b trial is expected to begin in Q1 2025, with initial data anticipated by mid-2026.
The trial aims to assess the safety and tolerability of the combination therapy and determine the recommended Phase 2 dose (RP2D). ORIC will sponsor the trial, while Johnson & Johnson will supply amivantamab.
ORIC retains the development and commercial rights to ORIC-114 and may expand its use with other agents. The company highlighted that ORIC-114 has shown promising systemic and intracranial activity in heavily pre-treated patients with EGFR/HER2 mutated NSCLC. The trial will further explore its efficacy in the first-line setting, both as a monotherapy and in combination with amivantamab.
In 2024, ORIC completed the monotherapy dose escalation portion of the Phase 1b trial for ORIC-114 in patients with advanced solid tumors. Based on these data, two provisional RP2D levels (80 mg and 120 mg QD) were selected for further evaluation.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in treatments for therapeutic resistance, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Jacob M. Chacko, M.D., will deliver a company overview presentation on Tuesday, January 14, 2025, at 11:15 a.m. PT.
The presentation will be accessible via live webcast through the investor section of ORIC's website at www.oricpharma.com. Interested parties who cannot attend the live presentation will have access to a replay of the webcast, which will remain available for 90 days after the event.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced the granting of inducement awards to a new non-executive employee who joined in December 2024. The grants, approved on January 2, 2025, include 16,400 non-qualified stock options and 2,800 restricted stock units.
The stock options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years. The restricted stock units will vest in three equal installments on each anniversary of the grant date. The exercise price for the stock options is set at the closing price of ORIC's common stock on January 2, 2025.
These inducement grants were made under the company's 2022 Inducement Equity Incentive Plan and were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, announced its participation in two upcoming investor conferences in December 2024. The company will join a fireside chat at the 7th Annual Evercore HEALTHCONx Conference on December 4 at 2:35 p.m. ET, and participate in the 'Novel Mechanisms in Oncology II' panel at Citi's 2024 Global Healthcare Conference on December 5 at 11:00 a.m. ET. Live webcasts will be accessible through ORIC's website, with replays available for 90 days after the events.
ORIC Pharmaceuticals reported Q3 2024 financial results and operational updates. The company presented preclinical data for ORIC-114, demonstrating potential best-in-class properties for treating EGFR exon 20 insertions. They announced clinical collaborations with Bayer and Johnson & Johnson for ORIC-944 trials in prostate cancer. Financial highlights include cash and investments of $282.4 million, expected to fund operations into late 2026. R&D expenses increased to $31.2 million in Q3 2024 from $22.4 million in Q3 2023, while G&A expenses rose to $7.1 million from $6.3 million in the same period.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in two upcoming investor conferences in November 2024. The company will be featured in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference on November 11 at 10:30 a.m. ET and the Jefferies London Healthcare Conference on November 21 at 12:00 p.m. GMT. Live webcasts of both discussions will be accessible through ORIC's investor website section, with replays available for 90 days after the events.
ORIC Pharmaceuticals announced the granting of inducement equity awards to two new non-executive employees who joined in October 2024. The grants include 61,800 non-qualified stock options and 10,400 restricted stock units. The stock options will vest 25% after one year, with remaining shares vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals presented data highlighting ORIC-114's potential as a best-in-class EGFR/HER2 inhibitor for treating EGFR exon 20 insertions and other atypical mutations. The brain-penetrant, orally bioavailable treatment demonstrated superior potency across EGFR mutational classes compared to other inhibitors. Key findings showed tumor regressions in all tested EGFR mutant models, with 100% tumor regressions in complex atypical mutant EGFR models. The drug displayed superior kinome selectivity and complete molecular responses in ctDNA from patients. Updated data from Phase 1b expansion cohorts is expected in H1 2025.
Candid Therapeutics, a clinical stage biotechnology company focused on T-cell engagers for autoimmune diseases, has appointed Angie You, Ph.D. and Dan Puckett to its board of directors. Dr. You, currently CEO of Architect Therapeutics, brings extensive experience in scaling organizations and advancing innovative products. She previously led Amunix Pharmaceuticals to a $1.2 billion acquisition by Sanofi. Mr. Puckett, former CFO of Shockwave Medical, played a key role in the company's growth leading to its $13.1 billion acquisition by Johnson & Johnson in 2024.
Ken Song, Chairman, President and CEO of Candid Therapeutics, expressed confidence that these proven leaders will be invaluable resources as the company aims to become a leader in treating autoimmune diseases. Both new board members have expressed enthusiasm for Candid's potential to transform autoimmune disease treatment through T-cell engagers.